AKT1 and neoplasm: Wenjing et al. have shown that Ex-4 can mitigate prostate cancer cell resistance to enzalutamide by targeting the PI3K/Akt/mTOR pathway, while the combined use of the two agents appears to improve the inhibitory actions of enzalutamide on tumor cell growth and proliferation and increase malignant cell chemosensitivity [81].